Cabergoline
- Generic Name
- Cabergoline
- Brand Names
- Dostinex
- Drug Type
- Small Molecule
- Chemical Formula
- C26H37N5O2
- CAS Number
- 81409-90-7
- Unique Ingredient Identifier
- LL60K9J05T
- Background
Cabergoline, an ergot derivative, is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome. Cabergoline possesses potent agonist activity on dopamine D2 receptors.
- Indication
For the treatment of hyperprolactinemic disorders, either idiopathic or due to prolactinoma (prolactin-secreting adenomas). May also be used to manage symptoms of Parkinsonian Syndrome as monotherapy during initial symptomatic management or as an adjunct to levodopa therapy during advanced stages of disease.
- Associated Conditions
- Hyperprolactinemia, Idiopathic hyperprolactinemic disorder
- Associated Therapies
- Inhibition of physiological lactation
A Study to Evaluate the Efficacy and Safety of Cabergoline Compared With Placebo for the Treatment of RLS
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2011-04-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 43
- Registration Number
- NCT00627003
A Study to Determine the Efficacy and Safety of Cabergoline for the Treatment of Patients With RLS
- First Posted Date
- 2008-02-28
- Last Posted Date
- 2008-10-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 361
- Registration Number
- NCT00625547
- Locations
- 🇨🇭
Pfizer Investigational Site, Zürich, Switzerland
Cardiac Valve Complications in Prolactinomas Treated With Cabergoline
- First Posted Date
- 2007-04-16
- Last Posted Date
- 2008-04-16
- Lead Sponsor
- Federico II University
- Target Recruit Count
- 50
- Registration Number
- NCT00460616
- Locations
- 🇮🇹
Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples, via S. Pansini 5 Naples, Italy
Cabergoline Reduces OHSS
- Conditions
- First Posted Date
- 2007-02-26
- Last Posted Date
- 2007-02-27
- Target Recruit Count
- 60
- Registration Number
- NCT00440258
Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease.
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2007-05-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 220
- Registration Number
- NCT00174239
- Locations
- 🇪🇸
Pfizer Investigational Site, Sevilla, Spain
Dopamine Turnover Rate as Surrogate Parameter for Diagnosis of Early Parkinson's Disease
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2012-12-18
- Lead Sponsor
- Technische Universität Dresden
- Target Recruit Count
- 39
- Registration Number
- NCT00153972
- Locations
- 🇩🇪
Department of Nuclear Medicine at the Technical University of Dresden, Dresden, Saxony, Germany
🇩🇪Department of Neurology at the Technical University of Dresden, Dresden, Saxony, Germany
Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease
- Conditions
- First Posted Date
- 2005-08-11
- Last Posted Date
- 2009-08-28
- Lead Sponsor
- Institute for Neurodegenerative Disorders
- Target Recruit Count
- 30
- Registration Number
- NCT00129181
- Locations
- 🇩🇪
Dept. of Neurology, University of Leipzig, Leipzig, Germany
🇮🇹Department of Neurological Sciences-University of Napoli, Naples, Italy
🇩🇪Dept. of Neurology Marburg, Phillips-Univ., Marburg, Germany
A Study of Cabergoline for the Treatment of Cocaine Dependence - 1
- Conditions
- Interventions
- First Posted Date
- 2002-04-08
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 140
- Registration Number
- NCT00033111
- Locations
- 🇺🇸
Torrance Clinic, Torrance, California, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.